Literature DB >> 21127951

Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki rats.

Wei Gao1, Sébastien Bihorel, Debra C DuBois, Richard R Almon, William J Jusko.   

Abstract

The dynamics of aging and type 2 diabetes (T2D) disease progression were investigated in normal [Wistar-Kyoto (WKY)] and diabetic [Goto-Kakizaki (GK)] rats and a mechanistic disease progression model was developed for glucose, insulin, and glycosylated hemoglobin (HbA1c) changes over time. The study included 30 WKY and 30 GK rats. Plasma glucose and insulin, blood glucose and HbA1c concentrations and hematological measurements were taken at ages 4, 8, 12, 16 and 20 weeks. A mathematical model described the development of insulin resistance (IR) and β-cell function with age/growth and diabetes progression. The model utilized transit compartments and an indirect response model to quantitate biomarker changes over time. Glucose, insulin and HbA1c concentrations in WKY rats increased to a steady-state at 8 weeks due to developmental changes. Glucose concentrations at 4 weeks in GK rats were almost twice those of controls, and increased to a steady-state after 8 weeks. Insulin concentrations at 4 weeks in GK rats were similar to controls, and then hyperinsulinemia occurred until 12-16 weeks of age indicating IR. Subsequently, insulin concentrations in GK rats declined to slightly below WKY controls due to β-cell failure. HbA1c showed a delayed increase relative to glucose. Modeling of HbA1c was complicated by age-related changes in hematology in rats. The diabetes model quantitatively described the glucose/insulin inter-regulation and HbA1c production and reflected the underlying pathogenic factors of T2D--IR and β-cell dysfunction. The model could be extended to incorporate other biomarkers and effects of various anti-diabetic drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21127951      PMCID: PMC3727409          DOI: 10.1007/s10928-010-9182-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  44 in total

1.  beta-cell function and viability in the spontaneously diabetic GK rat: information from the GK/Par colony.

Authors:  B Portha; M H Giroix; P Serradas; M N Gangnerau; J Movassat; F Rajas; D Bailbe; C Plachot; G Mithieux; J C Marie
Journal:  Diabetes       Date:  2001-02       Impact factor: 9.461

Review 2.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

3.  Insulin signalling and the regulation of glucose and lipid metabolism.

Authors:  A R Saltiel; C R Kahn
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

Review 4.  Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities.

Authors:  Derek LeRoith
Journal:  Am J Med       Date:  2002-10-28       Impact factor: 4.965

Review 5.  Drug treatment effects on disease progression.

Authors:  P L Chan; N H Holford
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

6.  A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes.

Authors:  B Topp; K Promislow; G deVries; R M Miura; D T Finegood
Journal:  J Theor Biol       Date:  2000-10-21       Impact factor: 2.691

7.  Gene expression analysis of hepatic roles in cause and development of diabetes in Goto-Kakizaki rats.

Authors:  Richard R Almon; Debra C DuBois; William Lai; Bai Xue; Jing Nie; William J Jusko
Journal:  J Endocrinol       Date:  2008-12-12       Impact factor: 4.286

8.  Morphological changes and increased sucrase and isomaltase activity in small intestines of insulin-deficient and type 2 diabetic rats.

Authors:  Tetsuya Adachi; Chisato Mori; Kenichi Sakurai; Nobuyuki Shihara; Kinsuke Tsuda; Koichiro Yasuda
Journal:  Endocr J       Date:  2003-06       Impact factor: 2.349

9.  Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats.

Authors:  K Yasuda; K Shimowada; M Uno; H Odaka; T Adachi; N Shihara; N Suzuki; A Tamon; K Nagashima; M Hosokawa; K Tsuda; Y Seino
Journal:  Diabetes Res Clin Pract       Date:  2003-02       Impact factor: 5.602

10.  Pharmacodynamics of glucose regulation by methylprednisolone. I. Adrenalectomized rats.

Authors:  Jin Y Jin; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2009-01       Impact factor: 1.627

View more
  12 in total

1.  Sleeve gastrectomy, but not duodenojejunostomy, preserves total beta-cell mass in Goto-Kakizaki rats evaluated by three-dimensional optical projection tomography.

Authors:  Eivind Grong; Bård Kulseng; Ingerid Brænne Arbo; Christoffer Nord; Maria Eriksson; Ulf Ahlgren; Ronald Mårvik
Journal:  Surg Endosc       Date:  2015-06-12       Impact factor: 4.584

2.  Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats.

Authors:  Wei Gao; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2012-02-29       Impact factor: 4.030

3.  Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats.

Authors:  Steve Choy; Willem de Winter; Mats O Karlsson; Maria C Kjellsson
Journal:  AAPS J       Date:  2016-05-31       Impact factor: 4.009

4.  Abnormal myosin phosphatase targeting subunit 1 phosphorylation and actin polymerization contribute to impaired myogenic regulation of cerebral arterial diameter in the type 2 diabetic Goto-Kakizaki rat.

Authors:  Khaled S Abd-Elrahman; Olaia Colinas; Emma J Walsh; Hai-Lei Zhu; Christine M Campbell; Michael P Walsh; William C Cole
Journal:  J Cereb Blood Flow Metab       Date:  2015-12-31       Impact factor: 6.200

5.  Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats.

Authors:  Yanguang Cao; Debra C Dubois; Hao Sun; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2011-09-08       Impact factor: 4.030

6.  Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.

Authors:  Wei Gao; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2010-12-14       Impact factor: 4.030

7.  The effect of duodenojejunostomy and sleeve gastrectomy on type 2 diabetes mellitus and gastrin secretion in Goto-Kakizaki rats.

Authors:  Eivind Grong; Ingerid Brænne Arbo; Ole Kristian Forstrønen Thu; Esther Kuhry; Bård Kulseng; Ronald Mårvik
Journal:  Surg Endosc       Date:  2014-08-09       Impact factor: 4.584

8.  Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.

Authors:  Ting Chen; Leonid Kagan; Donald E Mager
Journal:  J Pharm Sci       Date:  2013-07-29       Impact factor: 3.534

9.  Modeling Disease Progression: Angiotensin II Indirectly Inhibits Nitric Oxide Production via ADMA Accumulation in Spontaneously Hypertensive Rats.

Authors:  Haidong Wang; Hao Jiang; Haochen Liu; Xue Zhang; Guimei Ran; Hua He; Xiaoquan Liu
Journal:  Front Physiol       Date:  2016-11-17       Impact factor: 4.566

10.  Multimodal Highlighting of Structural Abnormalities in Diabetic Rat and Human Corneas.

Authors:  Laura Kowalczuk; Gaël Latour; Jean-Louis Bourges; Michèle Savoldelli; Jean-Claude Jeanny; Karsten Plamann; Marie-Claire Schanne-Klein; Francine Behar-Cohen
Journal:  Transl Vis Sci Technol       Date:  2013-03-04       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.